STA Pharmaceutical: Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

Pasithea Therapeutics Corp. today announced its contract with WuXi STA, a subsidiary of WuXi AppTec, to manufacture the active pharmaceutical ingredient ("API") for Pasithea's macrocyclic, next-generation MEK Inhibitor, PAS-004 (formerly CIP-137401).